nach oben

Current Bladder Dysfunction Reports

Erschienen in:

16.08.2017 | Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)

Bulking Agents in the Management of Urinary Incontinence: Dead or Alive?

verfasst von: Wayne Kwun Wai Chan, Peggy Sau Kwan Chu

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Although urethral bulking therapy has been available for more than 50 years, the ideal agent is still lacking and its result is considered inferior to surgery. In this review, we summarize the latest advances and evidences in the field of urethral bulking agents for treatment of stress urinary incontinence (SUI).

Recent Findings

The use of ultrasound evaluation post-urethral bulking provides insights for the optimal position and configuration of the bulking agent. Novel agents are available and show promising results in pre-clinical and clinical studies. More clinical data is available for currently available agent, e.g., Bulkamid. The field of cell-based urethral injection and regenerative medicine provides exciting future in treatment of SUI.

Summary

Urethral bulking therapy remains important in the treatment of SUI especially in high medical risk group or patients with recurrent SUI post-surgery. Further researches in novel bulking agents and regenerative medicine may further enhance its role and eliminate its current limitations.

Kelly HA DW. Urinary incontinence in women without manifest injury to the bladder. Surg Gynecol Obstet. 1914:444–50.

Murless BC. The injection treatment of stress incontinence. J Obstet Gynaecol Br Emp. 1938:67–73.

Anger JT, Weinberg AE, Albo ME, Smith AL, Kim J-H, Rodriguez LV, et al. Trends in surgical management of stress urinary incontinence among female Medicare beneficiaries. Urology. 2009;74:283–7. doi:10.1016/j.urology.2009.02.011.CrossRefPubMedPubMedCentral

Kong WG, Vasavada SP. Is injection therapy for stress urinary incontinence dead? Yes Urology. 2009;73:9–10. doi:10.1016/j.urology.2008.05.049.CrossRefPubMed

Dmochowski RR, Appell RA. Injectable agents in the treatment of stress urinary incontinence in women: where are we now? Urology. 2000;56:32–40.CrossRefPubMed

Reynolds WS, Dmochowski RR. Urethral bulking: a urology perspective. Urol Clin North Am. 2012;39:279–87. doi:10.1016/j.ucl.2012.05.002.CrossRefPubMed

Bent AE, Foote J, Siegel S, Faerber G, Chao R, Gormley EA. Collagen implant for treating stress urinary incontinence in women with urethral hypermobility. J Urol. 2001;166:1354–7.CrossRefPubMed

Lose G, Sorensen HC, Axelsen SM, Falconer C, Lobodasch K, Safwat T. An open multicenter study of polyacrylamide hydrogel (Bulkamid®) for female stress and mixed urinary incontinence. Int Urogynecol J. 2010;21:1471–7. doi:10.1007/s00192-010-1214-1.CrossRefPubMedPubMedCentral

Cespedes RD, Serkin FB. Is injection therapy for stress urinary incontinence dead? No Urology. 2009;73:11–3. doi:10.1016/j.urology.2008.05.048.CrossRef

10.

• Hegde A, Smith AL, Aguilar VC, Davila GW. Three-dimensional endovaginal ultrasound examination following injection of Macroplastique for stress urinary incontinence: outcomes based on location and periurethral distribution of the bulking agent. Int Urogynecol J. 2013;24:1151–9. doi:10.1007/s00192-012-1983-9. This paper presented a large group of patients with their transvaginal ultrasound findings post-urethral bulking injection and suggested the optimal location of bulking agents. CrossRefPubMed

11.

Yune JJ, Quiroz L, Nihira MA, Siddighi S, O’Leary DE, Santiago A, et al. The location and distribution of transurethral bulking agent: 3-dimensional ultrasound study. Female Pelvic Med Reconstr Surg. 2016;22:98–102. doi:10.1097/SPV.0000000000000217.CrossRefPubMed

12.

Unger CA, Barber MD, Walters MD. Ultrasound evaluation of the urethra and bladder neck before and after transurethral bulking. Female Pelvic Med Reconstr Surg. 2016;22:118–22. doi:10.1097/SPV.0000000000000250.CrossRefPubMed

13.

Dmochowski R, Appell RA. Advancements in minimally invasive treatments for female stress urinary incontinence: radiofrequency and bulking agents. Curr Urol Rep. 2003;4:350–5.CrossRefPubMed

14.

Ghoniem G, Corcos J, Comiter C, Bernhard P, Westney OL, Herschorn S. Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. J Urol. 2009;181:204–10. doi:10.1016/j.juro.2008.09.032.CrossRefPubMed

15.

Ghoniem G, Corcos J, Comiter C, Westney OL, Herschorn S. Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. J Urol. 2010;183:1444–9. doi:10.1016/j.juro.2009.12.038.CrossRefPubMed

16.

• Ghoniem GM, Miller CJ. A systematic review and meta-analysis of Macroplastique for treating female stress urinary incontinence. Int Urogynecol J. 2013;24:27–36. doi:10.1007/s00192-012-1825-9. This paper provided the pooled analysis of 20 years of researches on clinical use of Macroplastique. CrossRefPubMed

17.

Zajda J, Farag F. Urolastic—a new bulking agent for the treatment of women with stress urinary incontinence: outcome of 12 months follow up. Adv Urol. 2013;2013:724082. doi:10.1155/2013/724082.CrossRefPubMedPubMedCentral

18.

Zajda J, Farag F. Urolastic for the treatment of women with stress urinary incontinence: 24-month follow-up. Cent European J Urol. 2015;68:334–8. doi:10.5173/ceju.2015.541.PubMedPubMedCentral

19.

Futyma K, Miotla P, Galczynski K, Baranowski W, Doniec J, Wodzislawska A, et al. An open multicenter study of clinical efficacy and safety of Urolastic, an injectable implant for the treatment of stress urinary incontinence: one-year observation. Biomed Res Int. 2015;2015:851823. doi:10.1155/2015/851823.CrossRefPubMedPubMedCentral

20.

•• Futyma K, Nowakowski L, Galczynski K, Miotla P, Rechberger T. Nonabsorbable urethral bulking agent—clinical effectiveness and late complications rates in the treatment of recurrent stress urinary incontinence after 2 years of follow-up. Eur J Obstet Gynecol Reprod Biol. 2016;207:68–72. doi:10.1016/j.ejogrb.2016.10.011. This paper presented the largest series of patients using Urolastic in the recurrent SUI setting. CrossRefPubMed

21.

Pai A, Al-Singary W. Durability, safety and efficacy of polyacrylamide hydrogel (Bulkamid(®)) in the management of stress and mixed urinary incontinence: three year follow up outcomes. Cent European J Urol. 2015;68:428–33. doi:10.5173/ceju.2015.647.CrossRefPubMedPubMedCentral

22.

Zivanovic I, Rautenberg O, Lobodasch K, von Bunau G, Walser C, Viereck V. Urethral bulking for recurrent stress urinary incontinence after midurethral sling failure. Neurourol Urodyn. 2016; doi:10.1002/nau.23007.

23.

Aref-Adib M, Lamb BW, Lee HB, Akinnawo E, Raza MMA, Hughes A, et al. Stem cell therapy for stress urinary incontinence: a systematic review in human subjects. Arch Gynecol Obstet. 2013;288:1213–21. doi:10.1007/s00404-013-3028-0.CrossRefPubMed

24.

Sebe P, Doucet C, Cornu J-N, Ciofu C, Costa P, de Medina SGD, et al. Intrasphincteric injections of autologous muscular cells in women with refractory stress urinary incontinence: a prospective study. Int Urogynecol J. 2011;22:183–9. doi:10.1007/s00192-010-1255-5.CrossRefPubMed

25.

Carr LK, Steele D, Steele S, Wagner D, Pruchnic R, Jankowski R, et al. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:881–3. doi:10.1007/s00192-007-0553-z.CrossRefPubMed

26.

Lee CN, Jang JB, Kim JY, Koh C, Baek JY, Lee KJ. Human cord blood stem cell therapy for treatment of stress urinary incontinence. J Korean Med Sci. 2010;25:813–6. doi:10.3346/jkms.2010.25.6.813.CrossRefPubMedPubMedCentral

27.

Hakim L, Endo M, Feola A, Soebadi DM, Deprest J, de Ridder D, et al. High-frequency micro-ultrasound: a novel method to assess external urethral sphincter function in rats following simulated birth injury. Neurourol Urodyn. 2015;34:264–9. doi:10.1002/nau.22555.CrossRefPubMed

28.

Carr LK, Robert M, Kultgen PL, Herschorn S, Birch C, Murphy M, et al. Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study. J Urol. 2013;189:595–601. doi:10.1016/j.juro.2012.09.028.CrossRefPubMed

29.

Peters KM, Dmochowski RR, Carr LK, Robert M, Kaufman MR, Sirls LT, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol. 2014;192:469–76. doi:10.1016/j.juro.2014.02.047.CrossRefPubMed

30.

Cornu J-N, Lizee D, Pinset C, Haab F. Long-term follow-up after regenerative therapy of the urethral sphincter for female stress urinary incontinence. Eur Urol. 2014;65:256–8. doi:10.1016/j.eururo.2013.09.022.CrossRefPubMed

31.

Kuismanen K, Sartoneva R, Haimi S, Mannerstrom B, Tomas E, Miettinen S, et al. Autologous adipose stem cells in treatment of female stress urinary incontinence: results of a pilot study. Stem Cells Transl Med. 2014;3:936–41. doi:10.5966/sctm.2013-0197.CrossRefPubMedPubMedCentral

32.

• Gras S, Klarskov N, Lose G. Intraurethral injection of autologous minced skeletal muscle: a simple surgical treatment for stress urinary incontinence. J Urol. 2014;192:850–5. doi:10.1016/j.juro.2014.04.005. This paper presented a novel, technically simple approach of cell therapy in treatment of SUI without the need of cell expansion or selection. CrossRefPubMed

33.

•• Mann-Gow TK, King BJ, El-Ghannam A, Knabe-Ducheyne C, Kida M, Dall OM, et al. Novel bioceramic urethral bulking agents elicit improved host tissue responses in a rat model. Adv Urol. 2016;2016:1282531. doi:10.1155/2016/1282531. This paper studied two potential novel bioceramic bulking agents which showed larger bulking effects in animal models than existing agents. CrossRefPubMedPubMedCentral

34.

Mann-Gow TK, Blaivas JG, King BJ, El-Ghannam A, Knabe C, Lam MK, et al. Rat animal model for preclinical testing of microparticle urethral bulking agents. Int J Urol. 2015;22:416–20. doi:10.1111/iju.12693.CrossRefPubMed

35.

Kunkle CM, Hallock JL, Hu X, Blomquist J, Thung SF, Werner EF. Cost utility analysis of urethral bulking agents versus midurethral sling in stress urinary incontinence. Female Pelvic Med Reconstr Surg. 2015;21:154–9. doi:10.1097/SPV.0000000000000173.CrossRefPubMed

Titel: Bulking Agents in the Management of Urinary Incontinence: Dead or Alive?
verfasst von: Wayne Kwun Wai Chan
Peggy Sau Kwan Chu
Publikationsdatum: 16.08.2017
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 3/2017
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-017-0439-y

Neu im Fachgebiet Urologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Bulking Agents in the Management of Urinary Incontinence: Dead or Alive?

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Urologie

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Endoscopic Treatment of Vesicoureteral Reflux

Preoperative Evaluation of Post-prostatectomy Urinary Incontinence: Examining the Evidence for Routine Use of Multichannel Urodynamics

Reliability and Reproducibility of Pediatric Urodynamic Studies

Diagnosis and Treatments for Vesico-Enteric Fistulas: a 2017 Current Review

Anti-incontinence Surgery in High-Risk Male Patients with Stress Urinary Incontinence—an Updated Review

Oral Medications in the Treatment of Bladder Overactivity

Neu im Fachgebiet Urologie

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie